Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
Author:
Publisher
Frontiers Media SA
Subject
Pharmacology (medical),Pharmacology
Reference34 articles.
1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015
2. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012
3. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;N. Engl. J. Med.,2017
4. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic;Chan;Ann. Oncol.,2018
5. The impact of sample storage time on calculating tumor mutation burden (TMB);Chen;J. Clin. Oncol.,2018
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immune checkpoint inhibitors in infectious disease;Immunological Reviews;2024-09-09
2. Le taux circulant de PD-L1 : un biomarqueur émergent de réponse aux inhibiteurs de checkpoints immunitaires;Bulletin du Cancer;2024-04
3. Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer;European Journal of Medical Research;2024-03-27
4. Immunotherapy-related biomarkers: Confirmations and uncertainties;Critical Reviews in Oncology/Hematology;2023-12
5. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma;Scientific Reports;2023-11-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3